Хантеров синдром (Serbian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Хантеров синдром" in Serbian language version.

refsWebsite

Global rank Serbian rank

14nih.gov

4^th place

8^th place

11doi.org

2^nd place

4^th place

4archive.org

6^th place

5^th place

3medscape.com

719^th place

468^th place

2semanticscholar.org

11^th place

23^rd place

1whonamedit.com

2,888^th place

3,693^rd place

1cochrane.org

7,609^th place

9,992^nd place

archive.org

Young ID, Harper PS (1982). „Incidence of Hunter's syndrome”. Hum. Genet. 60 (4): 391—2. PMID 6809596. S2CID 9667145. doi:10.1007/BF00569230.
Lowry, R. B.; Applegarth, D. A.; Toone, J. R.; MacDonald, E; Thunem, N. Y. (август 1990). „An update on the frequency of mucopolysaccharide syndromes in British Columbia.”. Hum Genet. 85 (3): 389—90. .
Young, I. D.; Harper, P. S. (1982). „Incidence of Hunter's syndrome.”. Hum Genet. 60 (4): 391—2.
Young, I. D.; Harper, P. S. (август 1983). „The natural history of the severe form of Hunter's syndrome: a study based on 52 cases.”. Dev Med Child Neurol. 25 (4): 481—9. .

cochrane.org

Da Silva, E. M.; Strufaldi, M. W.; Andriolo, R. B.; Silva, L. A. (2016). „Liječenje mukopolisaharidoze tipa II (Hunterov sindrom) doknadom enzima s pomoću idursulfaze”. The Cochrane Database of Systematic Reviews. cochrane.org, 4 veljače 2016. 2016 (2): CD008185. PMC 7173756 . PMID 26845288. doi:10.1002/14651858.CD008185.pub4. Приступљено 18. 6. 2018.

doi.org

Hunter, C. A. (1917). „A Rare Disease in Two Brothers”. Proceedings of the Royal Society of Medicine. London. 10 (Sect Study Dis Child): 104—116. PMC 2018097 . PMID 19979883. doi:10.1177/003591571701001833.
Giugliani, R. (2012). „Mucopolysacccharidoses: From understanding to treatment, a century of discoveries”. Genetics and Molecular Biology. 35 (4 (suppl)): 924—931. PMC 3571427 . PMID 23411665. doi:10.1590/s1415-47572012000600006.
Young ID, Harper PS (1982). „Incidence of Hunter's syndrome”. Hum. Genet. 60 (4): 391—2. PMID 6809596. S2CID 9667145. doi:10.1007/BF00569230.
Scarpa, Maurizio; Almássy, Zsuzsanna; Beck, Michael; Bodamer, Olaf; Bruce, Iain A.; De Meirleir, Linda; Guffon, Nathalie; Guillén-Navarro, Encarna; Hensman, Pauline; Jones, Simon; Kamin, Wolfgang; Kampmann, Christoph; Lampe, Christina; Lavery, Christine A.; Leão Teles, Elisa; Link, Bianca; Lund, Allan M.; Malm, Gunilla; Pitz, Susanne; Rothera, Michael; Stewart, Catherine; Tylki-Szymańska, Anna; Van Der Ploeg, Ans; Walker, Robert; Zeman, Jiri; Wraith, James E.; Hunter Syndrome Europena Expert Council (2011). „Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease”. Orphanet Journal of Rare Diseases. 6: 72. PMC 3223498 . PMID 22059643. doi:10.1186/1750-1172-6-72 .
Garcia, A. R.; Dacosta, J. M.; Pan, J.; Muenzer, J.; Lamsa, J. C. (2007). „Preclinical dose ranging studies for enzyme replacement therapy with idursulfase in a knock-out mouse model of MPS II”. Molecular Genetics and Metabolism. 91 (2): 183—190. PMID 17459751. doi:10.1016/j.ymgme.2007.03.003.
Zareba, G. (2007). „Idursulfase in Hunter syndrome treatment”. Drugs of Today (Barcelona, Spain : 1998). 43 (11): 759—767. PMID 18174963. doi:10.1358/dot.2007.43.11.1157619.
Clarke, L. A. (2008). „Idursulfase for the treatment of mucopolysaccharidosis II”. Expert Opinion on Pharmacotherapy. 9 (2): 311—317. PMID 18201153. S2CID 73153880. doi:10.1517/14656566.9.2.311.
Wraith, J. E.; Scarpa, M.; Beck, M.; Bodamer, O. A.; De Meirleir, L.; Guffon, N.; Meldgaard Lund, A.; Malm, G.; Van Der Ploeg, A. T.; Zeman, J. (2008). „Mucopolysaccharidosis type II (Hunter syndrome): A clinical review and recommendations for treatment in the era of enzyme replacement therapy”. European Journal of Pediatrics. 167 (3): 267—277. PMC 2234442 . PMID 18038146. doi:10.1007/s00431-007-0635-4.
Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. (2011). „DrugBank 3.0: A comprehensive resource for 'omics' research on drugs”. Nucleic Acids Research. 39 (Database issue): D1035—41. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126.
Wishart, D. S.; Knox, C.; Guo, A. C.; Cheng, D.; Shrivastava, S.; Tzur, D.; Gautam, B.; Hassanali, M. (2008). „DrugBank: A knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.
Da Silva, E. M.; Strufaldi, M. W.; Andriolo, R. B.; Silva, L. A. (2016). „Liječenje mukopolisaharidoze tipa II (Hunterov sindrom) doknadom enzima s pomoću idursulfaze”. The Cochrane Database of Systematic Reviews. cochrane.org, 4 veljače 2016. 2016 (2): CD008185. PMC 7173756 . PMID 26845288. doi:10.1002/14651858.CD008185.pub4. Приступљено 18. 6. 2018.

medscape.com

emedicine.medscape.com

Germaine L, Defendi (18. 4. 2023). „Background, Hunter Syndrome (Mucopolysaccharidosis Type II)”. emedicine.medscape.com. Приступљено 16. 6. 2018.
Germaine L Defendi, Sanfilippo Syndrome (Mucopolysaccharidosis Type III) Меdscape
Germaine L Defendi Sly Syndrome (Mucopolysaccharidosis Type VII) Меdscape

nih.gov

ncbi.nlm.nih.gov

Hunter, C. A. (1917). „A Rare Disease in Two Brothers”. Proceedings of the Royal Society of Medicine. London. 10 (Sect Study Dis Child): 104—116. PMC 2018097 . PMID 19979883. doi:10.1177/003591571701001833.
Giugliani, R. (2012). „Mucopolysacccharidoses: From understanding to treatment, a century of discoveries”. Genetics and Molecular Biology. 35 (4 (suppl)): 924—931. PMC 3571427 . PMID 23411665. doi:10.1590/s1415-47572012000600006.
Young ID, Harper PS (1982). „Incidence of Hunter's syndrome”. Hum. Genet. 60 (4): 391—2. PMID 6809596. S2CID 9667145. doi:10.1007/BF00569230.
Scarpa, Maurizio; Almássy, Zsuzsanna; Beck, Michael; Bodamer, Olaf; Bruce, Iain A.; De Meirleir, Linda; Guffon, Nathalie; Guillén-Navarro, Encarna; Hensman, Pauline; Jones, Simon; Kamin, Wolfgang; Kampmann, Christoph; Lampe, Christina; Lavery, Christine A.; Leão Teles, Elisa; Link, Bianca; Lund, Allan M.; Malm, Gunilla; Pitz, Susanne; Rothera, Michael; Stewart, Catherine; Tylki-Szymańska, Anna; Van Der Ploeg, Ans; Walker, Robert; Zeman, Jiri; Wraith, James E.; Hunter Syndrome Europena Expert Council (2011). „Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease”. Orphanet Journal of Rare Diseases. 6: 72. PMC 3223498 . PMID 22059643. doi:10.1186/1750-1172-6-72 .
Garcia, A. R.; Dacosta, J. M.; Pan, J.; Muenzer, J.; Lamsa, J. C. (2007). „Preclinical dose ranging studies for enzyme replacement therapy with idursulfase in a knock-out mouse model of MPS II”. Molecular Genetics and Metabolism. 91 (2): 183—190. PMID 17459751. doi:10.1016/j.ymgme.2007.03.003.
Zareba, G. (2007). „Idursulfase in Hunter syndrome treatment”. Drugs of Today (Barcelona, Spain : 1998). 43 (11): 759—767. PMID 18174963. doi:10.1358/dot.2007.43.11.1157619.
Clarke, L. A. (2008). „Idursulfase for the treatment of mucopolysaccharidosis II”. Expert Opinion on Pharmacotherapy. 9 (2): 311—317. PMID 18201153. S2CID 73153880. doi:10.1517/14656566.9.2.311.
Burrow, T. A.; Leslie, N. D. (2008). „Review of the use of idursulfase in the treatment of mucopolysaccharidosis II”. Biologics : Targets & Therapy. 2 (2): 311—320. PMC 2721351 . PMID 19707363.
Adam, M. P.; Mirzaa, G. M.; Pagon, R. A.; Wallace, S. E.; Bean LJH; Gripp, K. W.; Amemiya, A.; Scarpa, M. (1993). Mucopolysaccharidosis Type II. PMID 20301451. Недостаје или је празан параметар |title= (помоћ)
Wraith, J. E.; Scarpa, M.; Beck, M.; Bodamer, O. A.; De Meirleir, L.; Guffon, N.; Meldgaard Lund, A.; Malm, G.; Van Der Ploeg, A. T.; Zeman, J. (2008). „Mucopolysaccharidosis type II (Hunter syndrome): A clinical review and recommendations for treatment in the era of enzyme replacement therapy”. European Journal of Pediatrics. 167 (3): 267—277. PMC 2234442 . PMID 18038146. doi:10.1007/s00431-007-0635-4.
Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. (2011). „DrugBank 3.0: A comprehensive resource for 'omics' research on drugs”. Nucleic Acids Research. 39 (Database issue): D1035—41. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126.
Wishart, D. S.; Knox, C.; Guo, A. C.; Cheng, D.; Shrivastava, S.; Tzur, D.; Gautam, B.; Hassanali, M. (2008). „DrugBank: A knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.
Da Silva, E. M.; Strufaldi, M. W.; Andriolo, R. B.; Silva, L. A. (2016). „Liječenje mukopolisaharidoze tipa II (Hunterov sindrom) doknadom enzima s pomoću idursulfaze”. The Cochrane Database of Systematic Reviews. cochrane.org, 4 veljače 2016. 2016 (2): CD008185. PMC 7173756 . PMID 26845288. doi:10.1002/14651858.CD008185.pub4. Приступљено 18. 6. 2018.

ninds.nih.gov

„Mucopolysaccharidoses Fact Sheet”. National Institute of Neurological Disorders and Stroke. 15. 6. 2017. Приступљено 15. 6. 2018.

semanticscholar.org

api.semanticscholar.org

Young ID, Harper PS (1982). „Incidence of Hunter's syndrome”. Hum. Genet. 60 (4): 391—2. PMID 6809596. S2CID 9667145. doi:10.1007/BF00569230.
Clarke, L. A. (2008). „Idursulfase for the treatment of mucopolysaccharidosis II”. Expert Opinion on Pharmacotherapy. 9 (2): 311—317. PMID 18201153. S2CID 73153880. doi:10.1517/14656566.9.2.311.

whonamedit.com

Hunter's syndrome (Charles A. Hunter) на сајту Who Named It